Predicting and monitoring cancer treatment response with diffusion-weighted MRI.

PubWeight™: 1.82‹?› | Rank: Top 3%

🔗 View Article (PMC 2918419)

Published in J Magn Reson Imaging on July 01, 2010

Authors

Harriet C Thoeny1, Brian D Ross

Author Affiliations

1: Department of Radiology, University Hospital of Bern, Inselspital, Bern, Switzerland.

Associated clinical trials:

PET/MR-imaging to Differentiate Between Responders and Non-responders Receiving Preoperative Chemotherapy | NCT02433301

Articles citing this

ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology (2010) 1.20

Towards personalized perioperative treatment for advanced gastric cancer. World J Gastroenterol (2014) 0.92

Breast MR with special focus on DW-MRI and DCE-MRI. Cancer Imaging (2011) 0.91

Diffusion-weighted MR imaging including bi-exponential fitting for the detection of recurrent or residual tumour after (chemo)radiotherapy for laryngeal and hypopharyngeal cancers. Eur Radiol (2012) 0.90

PET/MRI in cancer patients: first experiences and vision from Copenhagen. MAGMA (2012) 0.89

Clinical oncologic applications of PET/MRI: a new horizon. Am J Nucl Med Mol Imaging (2014) 0.89

Therapy response with diffusion MRI: an update. Cancer Imaging (2012) 0.87

Gradient nonlinearity correction to improve apparent diffusion coefficient accuracy and standardization in the american college of radiology imaging network 6698 breast cancer trial. J Magn Reson Imaging (2015) 0.87

Assessing reproducibility of diffusion-weighted magnetic resonance imaging studies in a murine model of HER2+ breast cancer. Magn Reson Imaging (2013) 0.86

Diffusion-weighted MRI in head and neck radiology: applications in oncology. Cancer Imaging (2011) 0.86

Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy. Br J Cancer (2013) 0.85

Pre-treatment diffusion-weighted MR imaging for predicting tumor recurrence in uterine cervical cancer treated with concurrent chemoradiation: value of histogram analysis of apparent diffusion coefficients. Korean J Radiol (2013) 0.85

Is there a benefit in using magnetic resonance imaging in the prediction of preoperative neoadjuvant therapy response in locally advanced rectal cancer? Int J Colorectal Dis (2013) 0.85

Multimodal imaging evaluation in staging of rectal cancer. World J Gastroenterol (2014) 0.85

A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer. Transl Oncol (2014) 0.85

Serial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101. Clin Cancer Res (2013) 0.85

Diffusion-weighted magnetic resonance application in response prediction before, during, and after neoadjuvant radiochemotherapy in primary rectal cancer carcinoma. Biomed Res Int (2013) 0.84

In vivo magnetic resonance imaging of sodium and diffusion in rat glioma at 21.1 T. Magn Reson Med (2011) 0.84

Thermal dose fractionation affects tumour physiological response. Int J Hyperthermia (2012) 0.84

Role of imaging in predicting response to neoadjuvant chemotherapy in gastric cancer. World J Gastroenterol (2014) 0.83

Breast DCE-MRI Kinetic Heterogeneity Tumor Markers: Preliminary Associations With Neoadjuvant Chemotherapy Response. Transl Oncol (2015) 0.83

DW-MRI as a Predictive Biomarker of Radiosensitization of GBM through Targeted Inhibition of Checkpoint Kinases. Transl Oncol (2013) 0.83

MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity. Br J Cancer (2014) 0.83

Diffusion MRI with Semi-Automated Segmentation Can Serve as a Restricted Predictive Biomarker of the Therapeutic Response of Liver Metastasis. Magn Reson Imaging (2015) 0.82

Combined PET imaging and diffusion-weighted imaging of intermediate and high-risk primary prostate carcinomas with simultaneous [18F] choline PET/MRI. PLoS One (2014) 0.80

Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy. Cancer Biol Ther (2014) 0.80

Whole-brain amide proton transfer (APT) and nuclear overhauser enhancement (NOE) imaging in glioma patients using low-power steady-state pulsed chemical exchange saturation transfer (CEST) imaging at 7T. J Magn Reson Imaging (2015) 0.79

Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancer. PLoS One (2015) 0.79

Current Status and New Developments in Breast MRI. Breast Care (Basel) (2011) 0.79

Role of quantitative magnetic resonance imaging parameters in the evaluation of treatment response in malignant tumors. Chin Med J (Engl) (2015) 0.79

Monitoring early response to anti-angiogenic therapy: diffusion-weighted magnetic resonance imaging and volume measurements in colon carcinoma xenografts. PLoS One (2014) 0.78

Combining standardized uptake value of FDG-PET and apparent diffusion coefficient of DW-MRI improves risk stratification in head and neck squamous cell carcinoma. Eur Radiol (2016) 0.78

Translational imaging endpoints to predict treatment response to novel targeted anticancer agents. Drug Resist Updat (2011) 0.78

Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model. Neoplasia (2016) 0.78

Interobserver reproducibility of diffusion-weighted MRI in monitoring tumor response to neoadjuvant therapy in esophageal cancer. PLoS One (2014) 0.78

Intravoxel incoherent motion imaging kinetics during chemoradiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: preliminary results from a prospective pilot study. NMR Biomed (2015) 0.77

DW-MRI of the urogenital tract: applications in oncology. Cancer Imaging (2010) 0.77

Early detection of Lewis lung carcinoma tumor control by irradiation using diffusion-weighted and dynamic contrast-enhanced MRI. PLoS One (2013) 0.77

Free-breathing 3D diffusion MRI for high-resolution hepatic metastasis characterization in small animals. Clin Exp Metastasis (2015) 0.76

Positron Emission Tomography for the Response Evaluation following Treatment with Chemotherapy in Patients Affected by Colorectal Liver Metastases: A Selected Review. Gastroenterol Res Pract (2015) 0.76

A study of the relationship of metabolic MR parameters to estrogen dependence in breast cancer xenografts. NMR Biomed (2015) 0.76

Evaluation of a Simplified Intravoxel Incoherent Motion (IVIM) Analysis of Diffusion-Weighted Imaging for Prediction of Tumor Size Changes and Imaging Response in Breast Cancer Liver Metastases Undergoing Radioembolization: A Retrospective Single Center Analysis. Medicine (Baltimore) (2016) 0.76

Imaging in clinical trials. Cancer Imaging (2010) 0.76

Role of diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient values in the detection of gastric carcinoma. Int J Clin Exp Med (2015) 0.75

Towards multidimensional radiotherapy: key challenges for treatment individualisation. Comput Math Methods Med (2015) 0.75

Intravoxel incoherent motion model-based analysis of diffusion-weighted magnetic resonance imaging with 3 b-values for response assessment in locoregional therapy of hepatocellular carcinoma. Onco Targets Ther (2016) 0.75

Early Detection of Treatment-Induced Mitotic Arrest Using Temporal Diffusion Magnetic Resonance Spectroscopy. Neoplasia (2016) 0.75

Chemotherapy response evaluation in a mouse model of gastric cancer using intravoxel incoherent motion diffusion-weighted MRI and histopathology. World J Gastroenterol (2017) 0.75

Various diffusion magnetic resonance imaging techniques for pancreatic cancer. World J Radiol (2015) 0.75

Strategies to optimize radiotherapy based on biological responses of tumor and normal tissue. Exp Ther Med (2012) 0.75

Hypo-Vascular Liver Metastases Treated with Transarterial chemoembolization: Assessment of Early Response by Volumetric Contrast-Enhanced and Diffusion-Weighted Magnetic Resonance Imaging. Transl Oncol (2016) 0.75

The distribution of the apparent diffusion coefficient as an indicator of the response to chemotherapeutics in ovarian tumour xenografts. Sci Rep (2017) 0.75

Systemic treatment in breast cancer: a primer for radiologists. Insights Imaging (2015) 0.75

Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians. Cancers (Basel) (2016) 0.75

Estimation of optimal b-value sets for obtaining apparent diffusion coefficient free from perfusion in non-small cell lung cancer. Phys Med Biol (2015) 0.75

Magnetic resonance imaging features of breast cancer according to intrinsic subtypes: correlations with neoadjuvant chemotherapy effects. Springerplus (2014) 0.75

The value of intravoxel incoherent motion model-based diffusion-weighted imaging for outcome prediction in resin-based radioembolization of breast cancer liver metastases. Onco Targets Ther (2016) 0.75

Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: a pilot study. Cancer Imaging (2013) 0.75

Intra- and interobserver variability of whole-tumour apparent diffusion coefficient measurements in nephroblastoma: a pilot study. Pediatr Radiol (2015) 0.75

Semiautomated Workflow for Clinically Streamlined Glioma Parametric Response Mapping. Tomography (2016) 0.75

Vasculature-specific MRI reveals differential anti-angiogenic effects of a biomimetic peptide in an orthotopic breast cancer model. Angiogenesis (2014) 0.75

Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents. J Clin Invest (2017) 0.75

Hypoxia in cervical cancer: from biology to imaging. Clin Transl Imaging (2017) 0.75

Magnetic resonance-imaging of the effect of targeted antiangiogenic gene delivery in a melanoma tumour model. Eur Radiol (2014) 0.75

Diffusion-weighted MR imaging of fetal lung maturation in sheep: effect of prenatal cortisone administration on ADC values. Eur Radiol (2013) 0.75

Early changes in the apparent diffusion coefficient and MMP-9 expression of a cervical carcinoma U14 allograft model following irradiation. Oncol Lett (2017) 0.75

Childhood extracranial neoplasms: the role of imaging in drug development and clinical trials. Pediatr Radiol (2015) 0.75

Value of Minimum Apparent Diffusion Coefficient on Magnetic Resonance Imaging as a Biomarker for Predicting Progression of Disease Following Surgery and Radiotherapy in Glial Tumors from a Tertiary Care Center in Northern India. J Neurosci Rural Pract (2017) 0.75

Articles cited by this

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74

SENSE: sensitivity encoding for fast MRI. Magn Reson Med (1999) 29.55

Generalized autocalibrating partially parallel acquisitions (GRAPPA). Magn Reson Med (2002) 20.68

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med (2009) 12.92

Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology (1988) 8.08

Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44

Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst (2000) 5.14

Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A (2005) 4.63

Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A (2005) 3.15

Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res (1997) 2.96

Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol (2008) 2.84

Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A (2000) 2.49

Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology (2009) 2.48

Water diffusion compartmentation and anisotropy at high b values in the human brain. Magn Reson Med (2000) 2.39

Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet (2002) 2.38

The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med (2009) 2.32

The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia (2006) 2.30

Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging (2006) 2.26

Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia (1999) 2.24

Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. Br J Cancer (1996) 2.20

Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology (2005) 2.18

Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia (2005) 2.17

Test liquids for quantitative MRI measurements of self-diffusion coefficient in vivo. Magn Reson Med (2000) 2.14

A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol (2009) 2.10

Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed (2009) 1.91

Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res (2009) 1.89

Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology (2008) 1.85

Intravoxel incoherent motion perfusion MR imaging: a wake-up call. Radiology (2008) 1.78

Monitoring thymidine kinase and ganciclovir-induced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging. Cancer Gene Ther (1998) 1.62

Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol (2007) 1.60

Preliminary results on the influence of chemoradiation on apparent diffusion coefficients of primary rectal carcinoma measured by magnetic resonance imaging. Strahlenther Onkol (2003) 1.51

A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia (2007) 1.50

Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging (2008) 1.48

Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: Initial results. Eur Radiol (2006) 1.45

Comparison and reproducibility of ADC measurements in breathhold, respiratory triggered, and free-breathing diffusion-weighted MR imaging of the liver. J Magn Reson Imaging (2008) 1.44

Magnetic Resonance Imaging and Spectroscopy: Application to Experimental Neuro-Oncology. Q Magn Reson Biol Med (1) 1.43

Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res (2004) 1.42

Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. Gene Ther (2000) 1.42

Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol Oncol (2008) 1.39

Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology (2005) 1.35

SMASH imaging. Magn Reson Imaging Clin N Am (1999) 1.35

Diffusion-weighted MRI in cervical cancer. Eur Radiol (2008) 1.34

Diffusion imaging for evaluation of tumor therapies in preclinical animal models. MAGMA (2004) 1.33

Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res (2007) 1.31

Diffusion-weighted MR imaging of metastatic disease of the spine: assessment of response to therapy. AJNR Am J Neuroradiol (2002) 1.29

An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res (2007) 1.26

The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther (2004) 1.25

Developing a quality control protocol for diffusion imaging on a clinical MRI system. Phys Med Biol (2004) 1.24

Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. Radiology (2008) 1.20

Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration. Neoplasia (2005) 1.18

Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. Transl Oncol (2008) 1.09

Optimization of chemical shift selective suppression of fat. Magn Reson Med (1998) 1.08

Cancer clinical trial outcomes: any progress in tumour-size assessment? Eur J Cancer (2008) 1.04

MRI: use of the inversion recovery pulse sequence. Clin Radiol (1998) 1.01

Advanced pancreatic cancer: the use of the apparent diffusion coefficient to predict response to chemotherapy. Br J Radiol (2009) 1.01

Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance. NMR Biomed (2006) 0.97

Added value of diffusion-weighted imaging in the MRI assessment of perilesional tumor recurrence after chemoembolization of hepatocellular carcinomas. J Magn Reson Imaging (2009) 0.93

Head and neck cancers. J Natl Compr Canc Netw (2005) 0.91

Early detection of therapeutic response to hepatic arterial infusion chemotherapy of liver metastases from colorectal cancer using diffusion-weighted MR imaging. Cardiovasc Intervent Radiol (2009) 0.90

Navigator respiratory-triggered diffusion-weighted imaging in the follow-up after hepatic radiofrequency ablation-initial results. J Magn Reson Imaging (2009) 0.88

Fat suppressed MRI of articular cartilage with a spatial-spectral excitation pulse. J Magn Reson Imaging (1999) 0.85

Diffusion-weighted MR imaging of the liver at 3.0 Tesla using TRacking Only Navigator echo (TRON): a feasibility study. J Magn Reson Imaging (2009) 0.85

MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model. J Magn Reson Imaging (2009) 0.83

Temporal and dose dependence of T2 and ADC at 9.4 T in a mouse model following single fraction radiation therapy. Med Phys (2009) 0.81

[Use of diffusion-weighted MRI in monitoring response of lymph node metastatic bladder cancer treated with chemotherary]. Nihon Hinyokika Gakkai Zasshi (2008) 0.78

Articles by these authors

(truncated to the top 100)

Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44

Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia (2011) 5.53

Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A (2005) 4.63

Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A (2005) 3.15

Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials (2007) 3.12

Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med (2012) 2.95

Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol (2010) 2.90

Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol (2008) 2.84

It's not just about anatomy: in vivo bioluminescence imaging as an eyepiece into biology. J Magn Reson Imaging (2002) 2.58

Towards hyperpolarized (13)C-succinate imaging of brain cancer. J Magn Reson (2007) 2.57

Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res (2006) 2.46

Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol (2007) 2.39

The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med (2009) 2.32

The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia (2006) 2.30

PASADENA hyperpolarization of succinic acid for MRI and NMR spectroscopy. J Am Chem Soc (2008) 2.27

A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol (2009) 2.10

Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci U S A (2002) 1.93

Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys (2005) 1.79

Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci (2003) 1.72

Molecular imaging of Akt kinase activity. Nat Med (2007) 1.68

Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev (2006) 1.66

A methodology for registration of a histological slide and in vivo MRI volume based on optimizing mutual information. Mol Imaging (2006) 1.63

Multi-system repeatability and reproducibility of apparent diffusion coefficient measurement using an ice-water phantom. J Magn Reson Imaging (2012) 1.57

PASADENA hyperpolarization of 13C biomolecules: equipment design and installation. MAGMA (2008) 1.56

Hyperpolarized water as an MR imaging contrast agent: feasibility of in vivo imaging in a rat model. Radiology (2012) 1.54

Clinical proton MR spectroscopy in central nervous system disorders. Radiology (2014) 1.53

Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging (2002) 1.53

A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia (2007) 1.50

Diffusion coefficient measurement using a temperature-controlled fluid for quality control in multicenter studies. J Magn Reson Imaging (2011) 1.50

Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res (2007) 1.48

Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad Sci U S A (2005) 1.44

Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res (2004) 1.42

Quality assurance of PASADENA hyperpolarization for 13C biomolecules. MAGMA (2008) 1.41

Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res (2011) 1.39

Radiation-induced changes in normal-appearing white matter in patients with cerebral tumors: a diffusion tensor imaging study. Int J Radiat Oncol Biol Phys (2008) 1.39

Diffusion imaging for therapy response assessment of brain tumor. Neuroimaging Clin N Am (2009) 1.38

Real-time molecular imaging of tricarboxylic acid cycle metabolism in vivo by hyperpolarized 1-(13)C diethyl succinate. J Am Chem Soc (2011) 1.36

Real-time evaluation of p53 oscillatory behavior in vivo using bioluminescent imaging. Cancer Res (2006) 1.34

Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res (2007) 1.31

Parahydrogen-induced polarization (PHIP) hyperpolarized MR receptor imaging in vivo: a pilot study of 13C imaging of atheroma in mice. NMR Biomed (2011) 1.27

Reduced glutamate neurotransmission in patients with Alzheimer's disease -- an in vivo (13)C magnetic resonance spectroscopy study. MAGMA (2003) 1.26

An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res (2007) 1.26

A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. Neoplasia (2008) 1.25

A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI. Mol Imaging (2003) 1.25

The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther (2004) 1.25

Dynamic imaging of emerging resistance during cancer therapy. Cancer Res (2006) 1.23

Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx (2005) 1.23

Noninvasive imaging of apoptosis and its application in cancer therapeutics. Clin Cancer Res (2008) 1.21

Inhibition of furin/proprotein convertase-catalyzed surface and intracellular processing by small molecules. J Biol Chem (2009) 1.20

Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy. Clin Cancer Res (2007) 1.16

The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. Cancer Res (2006) 1.15

Diffusion imaging: insight to cell status and cytoarchitecture. Neuroimaging Clin N Am (2006) 1.15

Voxel-by-voxel functional diffusion mapping for early evaluation of breast cancer treatment. Inf Process Med Imaging (2009) 1.15

Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS One (2011) 1.12

Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy. Clin Cancer Res (2010) 1.10

Molecular imaging of gene expression and efficacy following adenoviral-mediated brain tumor gene therapy. Mol Imaging (2003) 1.10

Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. Transl Oncol (2008) 1.09

Cardiovascular applications of hyperpolarized contrast media and metabolic tracers. Exp Biol Med (Maywood) (2009) 1.06

Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. Mol Cancer Ther (2012) 1.06

Sodium magnetic resonance imaging of chemotherapeutic response in a rat glioma. Magn Reson Med (2005) 1.01

Nuclear localized phosphorylated FADD induces cell proliferation and is associated with aggressive lung cancer. Cell Cycle (2005) 1.01

Fluorine-19 NMR chemical shift probes molecular binding to lipid membranes. J Phys Chem B (2008) 1.00

Intravoxel water diffusion heterogeneity imaging of human high-grade gliomas. NMR Biomed (2010) 1.00

Sodium and proton diffusion MRI as biomarkers for early therapeutic response in subcutaneous tumors. Magn Reson Imaging (2006) 0.99

Comparison of apparent diffusion coefficients and distributed diffusion coefficients in high-grade gliomas. J Magn Reson Imaging (2010) 0.99

In vivo characterization of fatty acids in human adipose tissue using natural abundance 1H decoupled 13C MRS at 1.5 T: clinical applications to dietary therapy. NMR Biomed (2003) 0.99

Clinical NOE 13C MRS for neuropsychiatric disorders of the frontal lobe. J Magn Reson (2008) 0.99

Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4. Clin Cancer Res (2005) 0.99

Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity. Anal Biochem (2007) 0.98

Continuous flow Overhauser dynamic nuclear polarization of water in the fringe field of a clinical magnetic resonance imaging system for authentic image contrast. J Magn Reson (2010) 0.98

Analysis and correction of gradient nonlinearity bias in apparent diffusion coefficient measurements. Magn Reson Med (2014) 0.98

Continuous arterial spin labeling using a train of adiabatic inversion pulses. J Magn Reson Imaging (2005) 0.98

Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance. NMR Biomed (2006) 0.97

Glial dysfunction in abstinent methamphetamine abusers. J Cereb Blood Flow Metab (2009) 0.97

DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma. PLoS One (2012) 0.96

Quantitative determination of extracellular glutamine concentration in rat brain, and its elevation in vivo by system A transport inhibitor, alpha-(methylamino)isobutyrate. J Neurochem (2004) 0.94

Diffusion-weighted MRI for assessment of early cancer treatment response. Curr Pharm Biotechnol (2010) 0.94

Targeted imaging and therapy of brain cancer using theranostic nanoparticles. Mol Pharm (2010) 0.94

Molecular imaging of protein kinases. Cell Cycle (2007) 0.93

Molecular imaging of glycogen synthase kinase-3beta and casein kinase-1alpha kinases. Anal Biochem (2010) 0.92

Fast volumetric spatial-spectral MR imaging of hyperpolarized 13C-labeled compounds using multiple echo 3D bSSFP. Magn Reson Imaging (2010) 0.92

Convection enhanced delivery of carboplatin in combination with radiotherapy for the treatment of brain tumors. J Neurooncol (2010) 0.91

Glial uptake of neurotransmitter glutamate from the extracellular fluid studied in vivo by microdialysis and (13)C NMR. J Neurochem (2002) 0.90

Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers. Clin Cancer Res (2010) 0.90

DCE and DW-MRI monitoring of vascular disruption following VEGF-Trap treatment of a rat glioma model. NMR Biomed (2011) 0.90

Imaging proteolytic activity in live cells and animal models. PLoS One (2013) 0.89

Kinetics of glial glutamine efflux and the mechanism of neuronal uptake studied in vivo in mildly hyperammonemic rat brain. J Neurochem (2006) 0.89

Enhancing Akt imaging through targeted reporter expression. Mol Imaging (2009) 0.88

Gd-enhanced cardiovascular MR imaging to identify left ventricular pseudoaneurysm. J Cardiovasc Magn Reson (2005) 0.88

Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. J Cell Biochem (2009) 0.88

Radiosynthesis and evaluation of 5-[125I]iodoindol-3-yl-beta-D-galactopyranoside as a beta-galactosidase imaging radioligand. Mol Imaging (2009) 0.87

Inhibition of vascular endothelial growth factor (VEGF)-A causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D. Clin Cancer Res (2006) 0.87

Ornithine transcarbamylase deficiency with persistent abnormality in cerebral glutamate metabolism in adults. Radiology (2009) 0.87

Molecular imaging of c-Met tyrosine kinase activity. Anal Biochem (2011) 0.87

Bioluminescence detection of cells having stabilized p53 in response to a genotoxic event. Mol Imaging (2004) 0.87

MR spectroscopy in diagnosis and neurological decision-making. Semin Neurol (2008) 0.87

Novel molecular imaging platform for monitoring oncological kinases. Cancer Cell Int (2010) 0.87

Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor--a pharmacokinetic study. J Neurooncol (2005) 0.87

Chronic electrographic seizure reduces glutamine and elevates glutamate in the extracellular fluid of rat brain. Brain Res (2010) 0.86

Evaluation of D-methionine as a novel oral radiation protector for prevention of mucositis. Clin Cancer Res (2008) 0.86